亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

1158 Preclinical antitumor activity of potent and orally bioavailable PROTAC hematopoietic progenitor kinase 1 (HPK1) degraders as monotherapy or combined with an anti-programmed death-1 (PD-1) antibody

作者
William L. Corwin,Albert M. DeBerardinis,Rebecca Conrad,Morena Scopel,Patri-ca Morgan,Sanjukta Chakraborty,Jenny Frenette,Rashaun S. Wilson,John Corradi,Kim Davenport,Gregory W. Cadelina,Jennifer Pizzano,Alexey V. Ishchenko,Erika M. V. Araujo,Keith R. Hornberger,Angela M. Cacace,Ignacio J. Juncadella
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A1323-A1323
标识
DOI:10.1136/jitc-2025-sitc2025.1158
摘要

Background HPK1 (MAP4K1), a serine/threonine protein kinase predominately expressed in the immune compartment, negatively regulates T-cell receptor signaling and immune activation. HPK1 is a promising therapeutic target for enhancing the antitumor immune response, and several small-molecule HPK1 inhibitors are in clinical trials. HPK1 also has kinase-independent regulatory roles in several innate immune cells, eg, dendritic and natural killer (NK) cells, potentially not addressed by small-molecule kinase inhibition. We characterized PROteolysis TArgeting Chimera (PROTAC) HPK1 degraders, which induce ubiquitination of HPK1 and its subsequent degradation by the proteasome.Methods PROTAC HPK1 degraders were characterized by biochemical, proteomic, and cell-based assays. Mechanistic studies were conducted in human peripheral blood mononuclear cells and various immune cells. Pharmacological efficacy and pharmacokinetic/pharmacodynamic/pathway engagement relationship were assessed in syngeneic tumor models as single agents or combined with an anti-PD-1 antibody. Multicolor, flow cytometry tumor-infiltrating lymphocyte analysis and RNAseq in syngeneic melanoma tumor-implanted mice provided mechanistic differentiation of the tumor immune landscape after PROTAC HPK1 degrader treatment.Results PROTAC HPK1 degraders exhibited half-maximal degradation concentrations of 1-20 nM, potent cellular pathway engagement (pSLP76 half-maximal inhibitory concentrations: 2-25 nM), and robust T-cell activity (interleukin-2 release half-maximal effective concentrations: 2-20 nM). PROTAC HPK1 degraders demonstrated the ability to reverse T-cell exhaustion, block suppressive effects of tumor-mediated metabolites, eg, prostaglandin E 2 and adenosine (return of interleukin-2 secretion to control levels), induce T cell and NK cell-mediated tumor cell death, and activate dendritic cells. PROTAC HPK1 degraders achieved robust HPK1 degradation (>80%) and efficient pathway engagement (>70% pSLP76 inhibition) at a single 30 mg/kg oral dose in naïve BALB/c mice. In a colonic syngeneic tumor model, PROTAC HPK1 degraders (30 mg/kg) showed greater tumor growth inhibition (TGI) compared with an anti-PD-1 antibody (>80% vs ~50%); combination of a PROTAC HPK1 degrader with an anti-PD-1 antibody resulted in 50% complete responders (5/10 mice). In a low-immunogenic, immune checkpoint blockade-resistant melanoma model, PROTAC HPK1 degraders elicited superior TGI (79%) vs an anti-PD-1 antibody (0) or HPK1 inhibitor (13%). PROTAC HPK1 degraders transcriptionally reprogrammed immune cells in the melanoma tumor microenvironment, with significantly increased (~2-fold) inflammatory monocytes and activated NK cells, and decreased infiltrating neutrophils compared with an anti-PD-1 antibody or HPK1 inhibitor.Conclusions We demonstrated pharmacological degradation of HPK1 has greater antitumor activity than HPK1 inhibitors or immune checkpoint blockade in preclinical models. These results support future investigation of PROTAC HPK1 degraders alone or combined with other agents in patients with certain cancers.Ethics Approval Animals were maintained in accordance with the guidelines of the Guide for the Care and Use of Laboratory Animals. All animal research protocol procedures were reviewed and approved by the Arvinas Animal Care and Use Committee.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明理的璎完成签到,获得积分10
5秒前
9秒前
美丽的忆彤完成签到,获得积分10
10秒前
Ava的应助被sun采纳,获得10
26秒前
33秒前
动听一德完成签到,获得积分10
33秒前
领导范儿的应助被ClaraClark591采纳,获得30
36秒前
44秒前
46秒前
sun发布了新的文献求助10
49秒前
ClaraClark591发布了新的文献求助30
51秒前
威武的又琴完成签到,获得积分10
55秒前
闪闪小凡完成签到,获得积分10
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
Tashanzhishi完成签到,获得积分10
1分钟前
优美的烙完成签到,获得积分10
1分钟前
打打的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
科目三的应助被科研通管家采纳,获得10
1分钟前
奔跑的应助被科研通管家采纳,获得10
1分钟前
愉快的惋庭完成签到,获得积分10
2分钟前
等待剑完成签到,获得积分10
2分钟前
2分钟前
Maestro_S的应助被爱学习的doge采纳,获得10
2分钟前
2分钟前
2分钟前
孙老师完成签到 ,获得积分10
2分钟前
AiQi完成签到 ,获得积分10
2分钟前
sfwrbh完成签到,获得积分10
2分钟前
多情的中蓝完成签到,获得积分10
3分钟前
甜蜜语堂完成签到,获得积分10
3分钟前
李爱国的应助被科研通管家采纳,获得10
3分钟前
Maestro_S的应助被科研通管家采纳,获得10
3分钟前
大医仁心完成签到 ,获得积分0
3分钟前
Ali发布了新的文献求助10
3分钟前
淡然的易槐完成签到,获得积分10
3分钟前
清脆妙梦发布了新的文献求助40
3分钟前
丰富的藏鸟完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808444
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478958